The premium GHRH + GHRP stack — tesamorelin’s visceral-fat-targeting firepower plus ipamorelin’s clean GH pulse. The most potent pulsatile GH protocol short of actual HGH.
A combined GHRH + GHRP protocol that pairs tesamorelin (the FDA-approved GHRH analog originally used for HIV lipodystrophy visceral fat) with ipamorelin (the selective GHRP with no cortisol or prolactin side effects).
It’s essentially a "premium CJC-1295 + Ipamorelin" — the tesamorelin component produces a stronger, more reliable GH pulse than CJC-1295 no-DAC, with specific preferential effects on visceral adipose tissue. The trade-off is higher cost and shorter reconstituted shelf life.
Tesamorelin is FDA approved (Egrifta) for HIV lipodystrophy; ipamorelin is not FDA approved. Both WADA prohibited (S2). The stack is used off-label; available as separate peptides or pre-mixed blend.
Potent GHRH analog with higher pituitary binding affinity and longer half-life than CJC-1295 no-DAC. Drives a larger, more reliable GH pulse. Strong preferential effect on visceral (deep belly) fat reduction via IGF-1-mediated lipolysis.
Selectively activates GHS-R without the cortisol/prolactin/aldosterone side effects of older GHRPs. Amplifies the GH pulse from tesamorelin without adding side-effect baggage.
Like CJC+Ipa, the combination produces a larger GH pulse than either component alone. With tesamorelin as the base, the pulse is noticeably stronger — reflected in both IGF-1 elevation and clinical visceral fat outcomes.
| Benefit | Evidence |
|---|---|
| Visceral fat loss | Tesamorelin’s Phase 3: 15–18% VAT reduction at 26 weeks; stack amplifies via ipamorelin pulse |
| Sleep quality | Pre-bed pulse restores slow-wave sleep reliably |
| Body composition | Lean mass preservation during fat loss; stronger than CJC+Ipa per dose |
| Liver fat / NAFLD | Tesamorelin reduces hepatic fat ~40% in NAFLD trials |
| Recovery | Faster soft-tissue recovery between training sessions |
| Skin quality | Increased collagen synthesis; thicker, healthier skin over 8–12 weeks |
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeBegin at 1 mg tesamorelin + 100 mcg ipamorelin for 2–4 weeks to assess water retention, glucose response, and overall tolerance. Titrate to 2 mg tesa if tolerated.
IGF-1 (expect ~50% rise at full dose), fasting glucose, HbA1c, lipids. Measure at baseline and every 3 months. DEXA or waist circumference at baseline and 12 weeks to track visceral fat change.
Commonly supplied as a pre-mixed blend (e.g. 5 mg tesamorelin + 5 mg ipamorelin in one vial). Can also be reconstituted separately.
10 mg tesa + 3 mg ipa blend + 2 mL BAC water = 5 mg/mL tesa + 1.5 mg/mL ipa
| Target (Tesa + Ipa) | Volume | Syringe Units |
|---|---|---|
| 1 mg + 300 mcg | 0.20 mL | 20 units |
| 1.5 mg + 450 mcg | 0.30 mL | 30 units |
| 2 mg + 600 mcg | 0.40 mL | 40 units |
Vial ratios vary by vendor — check your label. If your blend isn’t 10/3 or you want a different tesa:ipa ratio, reconstitute the two peptides separately instead.
Pre-filled with a typical Tesamorelin + Ipamorelin setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Elevated GH/IGF-1 may promote existing tumor growth. Avoid with any malignancy history.
Looking for Tesamorelin + Ipamorelin? We recommend NextGen Peptides — third-party tested, fast shipping, and trusted by the StackTrax community.
10% off with code
Exclusive StackTrax discount
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeIt is a combined GHRH + GHRP protocol. Tesamorelin is a potent GHRH analog with higher pituitary binding affinity and longer half-life than CJC-1295 no-DAC, driving a larger, more reliable GH pulse with a strong preferential effect on visceral fat. Ipamorelin selectively activates the ghrelin receptor (GHS-R) without the cortisol, prolactin, or aldosterone side effects of older GHRPs. Like CJC + Ipa, the combination produces a larger GH pulse than either component alone, but with tesamorelin as the base the pulse is noticeably stronger.
Tesamorelin is FDA approved as Egrifta for HIV lipodystrophy (excess visceral fat in HIV patients). Ipamorelin is not FDA approved. The combined stack is used off-label and is available as separate peptides or as a pre-mixed blend. Both components are WADA prohibited under S2 (Peptide Hormones, Growth Factors).
The standard community stack is 1 to 2 mg tesamorelin plus 100 to 300 mcg ipamorelin once daily pre-bed (with an optional second morning pulse), SubQ on an empty stomach (more than 2 hours post-meal), cycled 3 to 6 months on with a 1 to 2 month break. A conservative start is 1 mg tesamorelin + 100 mcg ipamorelin for 2 to 4 weeks to assess water retention, glucose response, and overall tolerance before titrating up to 2 mg tesa.
Once daily pre-bed is the standard timing, with an optional second morning pulse. Injections should be SubQ in a fasted state, more than 2 hours after a meal, because food (especially carbohydrates and fats) blunts the GH pulse. Pre-bed dosing reliably restores slow-wave sleep, and vivid dreams from the pre-bed dose are a common reported effect.
Track IGF-1 (expect roughly a 50% rise at full dose), fasting glucose, HbA1c, and lipids at baseline and every 3 months. DEXA or waist circumference at baseline and 12 weeks tracks visceral fat change. Tesamorelin's Phase 3 trials in HIV lipodystrophy showed a 15 to 18% VAT reduction at 26 weeks, and tesamorelin reduces hepatic fat by roughly 40% in NAFLD trials, so liver imaging may be relevant if NAFLD is the target.
Common effects include injection site reactions (tesamorelin can sting), arthralgia or joint discomfort, water retention or edema, numbness, tingling, or mild carpal tunnel symptoms, vivid dreams from pre-bed dosing, and short-lived facial flushing. Less common effects include mild fasting glucose elevation, headache, and mild nausea. Tesamorelin is also fragile to reconstitute: water down the wall slowly, gently roll the vial, and use the reconstituted product within 7 days (tesamorelin limits the shelf life).
Do not use with active or prior cancer, pituitary tumor, active retinopathy, pregnancy or breastfeeding, or under age 25. Use caution with diabetes, insulin resistance, thyroid disorders, cardiovascular disease, and carpal tunnel. Elevated GH/IGF-1 may promote existing tumor growth, so avoid with any malignancy history. WADA prohibits the stack at all times.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.